X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Recognizing National Sickle Cell Awareness Month

By Anne McDonald Pritchett, PhD  |    September 23, 2022
September is National Sickle Cell Awareness Month and a time for us to underscore the biopharmaceutical industry’s ongoing commitment to improve the lives of patients, families and communities...   Read More

Partnerships are driving global COVID-19 treatment access

By Megan Van Etten  |    September 22, 2022
Through the constant efforts of U.S. innovators and their global partners, COVID-19 treatments have continued to be distributed to patients around the world — changing the pandemic’s treatment...   Read More

The dangers of expanding the TRIPS waiver

By Megan Van Etten  |    September 19, 2022
World Trade Organization (WTO) members, including the United States, are considering waiving commitments to honor certain intellectual property (IP) rights on COVID-19 treatments, following a harmful...   Read More

New data: The 340B program is driving up costs for patients and our health care system

By Nicole Longo  |    September 15, 2022
Guess what? The 340B program grew, yet again, hitting a whopping $43.9 billion in sales at the discounted 340B price in 2021. But there has not been evidence of corresponding growth in care provided...   Read More

Timely reauthorization of PDUFA and BsUFA is vital to the FDA’s review of medicines

By Andrew Powaleny  |    September 12, 2022
As we’ve discussed on this blog before, timely reauthorization of the Prescription Drug User Fee Act (PDUFA) and the Biosimilar User Fee Act (BsUFA) is critical to sustaining the U.S. Food and Drug...   Read More

Navigating the patient experience: Burdens and barriers standing between patients and their care

By Mark Keida  |    September 12, 2022
Health care affordability is not the only hurdle facing patients, according to PhRMA’s third Patient Experience Survey (PES). The latest PES report exposes another crucial problem: the frustration...   Read More

CMS coverage policies restrict patient access to important treatment options for Alzheimer’s disease

By Gabby Migliara  |    September 1, 2022
There’s been a lot of discussion this year about the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) for new Alzheimer’s treatments finalized earlier this year in...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates